Full Press Release Details
Kamada Awarded $22 Million Extension of Canadian
Rehovot, Israel, and Hoboken, NJ, October 19,
2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty
plasma-derived therapeutics, announced today that the Company was awarded an extension of an existing tender from the Canadian Blood Services
(CBS) for the supply of four IgG products, CYTOGAM , HEPAGAM , VARIZIG and WINRHO SDF, for an additional three years
for an approximate total value of $22 million. This award secures the ongoing sales of those products in the Canadian market. The four
commercial products, approved by Health Canada and the U.S. Food and Drug Administration (FDA), were acquired by Kamada in November 2021.
CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec. The extension with CBS
is for a three-year period, commencing on April 1, 2023, with an option to extend for up to two additional years.
award, together with KAMRAB as the primary anti-Rabies IgG product used in Canada, validates our position as the leading specialty
IgG company in that important geography," said Amir London, Kamada's Chief Executive Officer. "This achievement represents
the second significant tender we have recently secured, following the new $11.4 million supply
agreement won for VARIZIG from an international organization operating principally in Latin
America. We remain confident that significant commercial potential exists for our IgG portfolio in international markets and intend
to continue pursuing additional contracts in key strategic territories."
Commercial manufacturing of CYTOGAM at Kamada's
Israeli manufacturing plant is expected to be initiated during 2023, following anticipated FDA and Health Canada approvals of the ongoing
tech transfer process. HEPAGAM, VARIZIG and WINRHO SDF are manufactured by Emergent BioSolutions (NYSE: EBS) at its facility in Winnipeg,
MB, Canada, under a contract development and manufacturing service agreement.
Kamada Ltd. (the "Company") is a vertically
integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products,
a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable
growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical
market. The Company's commercial products portfolio includes its developed and FDA approved products GLASSIA and KEDRAB
as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM , HEPAGAM B , VARIZIG and WINRHO SDF.
The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial
products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S.,
Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of
development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting
the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise
and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties
and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals,
are expected to be launched in Israel through 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's
lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
Cautionary Note Regarding Forward-Looking
This release includes forward-looking statements
within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements
regarding: 1) the prospects of aggregate revenues of approximately $22 million for the tender extension, which would commence on April
1, 2023, 2) positive statements regarding Kamada's ability to grow sales of its newly acquired portfolio of four FDA-approved plasma-derived
specialty IgGs in the international markets, 3) Kamada's intention to continue pursuing additional commercial contracts in key strategic
territories, 4) positive statements regarding validation of Kamada's position as the leading specialty IgG company in Canada, 5) the commercial
manufacturing of CYTOGAM at Kamada's Israeli manufacturing plant initiating during 2023, and 6) anticipated FDA and Health Canada
approvals of the on-going tech transfer process. Forward-looking statements are based on Kamada's current knowledge and its present
beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and
the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors
including, but not limited to, the continued evolvement of the COVID-19 pandemic, its scope, effect and duration, disruption to the supply
chain due to COVID-19 pandemic, Kamada's ability to successfully integrate the new product portfolio into its current product portfolio,
regulatory delays, changes with FDA and other regulatory agencies' rules and regulations, prevailing market conditions and the impact
of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada's filings
with the U.S. Securities and Exchange Commission (the "SEC") including those discussed in its most recent Annual Report on
Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC's
website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes
no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required
Chief Financial Officer
LifeSci Advisors, LLC